Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 289

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 289
---
 considering the Business Combination, the APx Board concluded that the Company met nearly all the above criteria. In particular, the APx Board considered the following positive factors, although not weighted or in any order of significance: • Competitive Strengths. The unique position of the Company in the healthcare space, supported by a unique joinder of genomics product offerings, with inroads into traditionally underserved markets as well as developed markets. The Company’s position is particularly unique, given the lack of other current market participants with the breadth of products and service offerings spanning deep genetic sequencing and microbiome analysis, with plans to increase these offerings with artificial intelligence -assistedinterpretation and processing, and AI Agents designed to interact directly with customers. Additionally, the Company’s strategy is unique relative its peers in that it maintains both a business -to-businessand business -to-business-to-consumergo to market strategy, while also maintaining a partnership approach with existing and deeply embedded healthcare market participants. • Attractive Valuation. The APx Board’s determination that based on the Company’s commercial potential, underpinned by their unique product offering and multi -channeldistribution approach, as well as their intellectual property portfolios, APx’s shareholders would acquire their shares in the Company at an attractive valuation in comparison to global private and public comparable companies examined by the APx Board. Quantitively, the APx Board considered that many comparable companies with significantly higher valuations incurred significant operating losses inherent in their respective EBITDA metrics, suggesting an inefficient operating model and making OmnigenicsAI’s valuation attractive in comparison, particularly given its ability to efficiently commercialize and scale. Additionally, as OmnigenicsAI’s unique, multi -facetedproduct offering make it difficult to compare to compare to other companies, and its peers who participate in one or more of its core competencies operate in emerging industries, EBITDA and revenue are not always reliable metrics for evaluation and comparison. Therefore, in analyzing OmnigenicsAI’s valuation, the APx Board took into consideration other factors, such as its ability to commercialize and scale, its total addressable market, its intellectual property portfolio and its unique, multi -facetedbusiness model. In estimating OmnigenicsAI’s total addressable market, the populations of 100 major Latin American cities were considered, each adjusted for the percentage of the population that is likely to be able to access out -of-pockethealth care. • Due Diligence. The results of APx’s due diligence investigation of the Company’s conducted by